×
  • Share
  • Email
  • Embed
  • Like
  • Private Content
 

Analysis of the US Retinal Therapeutics Market

by on Jan 17, 2014

  • 584 views

Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market ...

Revamped Therapies Preventing Visual Impairment Primed to Revolutionize US Retinal Therapeutics Market

Frost & Sullivan: Ripe for innovative, non-invasive treatments, the market will almost double by 2017

The need for effective and patient-friendly treatment of retinal diseases to avoid visual impairment is driving the retinal therapeutics market in the U.S. Vascular endothelial growth factor (VEGF) inhibitors dominate the market as they are a safe and effective option to treat age-related macular degeneration (AMD), diabetic macular edema (DME), and retinal vein occlusion (RVO). Although highly efficacious, existing VEGF treatments require frequent, invasive intravitreal injections. Thus, growth opportunities exist for new therapies with comparable efficacy but improved dosing and administration.

New analysis from Frost & Sullivan's (http://www.lifesciences.frost.com) Analysis of the US Retinal Therapeutics Market finds the market earned revenue of $2.45 billion in 2012 and estimates this to almost double to $4.15 billion in 2017.

For more information on this research, please email Jennifer Carson, Corporate Communications, at jennifer.carson@frost.com, with your full name, company name, job title, telephone number, company email address, company website, city, state and country.

Statistics

Views

Total Views
584
Views on SlideShare
584
Embed Views
0

Actions

Likes
1
Downloads
4
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via SlideShare as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
Post Comment
Edit your comment

Analysis of the US Retinal Therapeutics Market Analysis of the US Retinal Therapeutics Market Presentation Transcript